About GNT

Translating discovery into possibility

General Nutraceutical Technology is a New York-based biotechnology company developing evidence-based interventions for allergic and inflammatory diseases.

Our mission

Improve quality of life—and save lives—through the identification, development, and commercialization of better therapeutics.

01

Founding purpose

Co-founded by Dr. Xiu-Min Li to move promising laboratory discoveries toward real-world use.

02

Internal pipeline

A portfolio of therapeutic programs supported by a network of academic and business affiliates.

03

Research network

Close collaboration with academic researchers in allergic disease, cancer, and infectious disease.

04

Development support

Private-foundation support, academic contracts, and partnerships that advance research and development.

NIH-supported development

Programs backed for translation

R43 · SBIR Phase I · 2019–2021

IgE Suppressing Berberine Nanomedicine for Treatment of Food Allergies

R44 · SBIR Phase II · 2023–2027

Phase II follow-on for IgE-suppressing berberine nanomedicine

R41 · STTR Phase I · 2023–2025

IgE-suppressing xanthopurpurin analog for multiple food allergies

R21 · NIAID · Awarded 2023

IgE-suppressing berberine nanomedicine for peanut and tree-nut allergies